Roche and Spark Therapeutics jointly announced that the Federal Trade Commission has made a request for documentary material and additional information as part of the FTC's review of Roche's pending acquisition deal of the gene therapy company for more than $4 billion. This is the fourth time the deadline has been extended, and with the third tender offer to expire June 14, the new deadline is now pushed back to July 31.
Tender offer for $4B acquisition of Spark by Roche pushed back again
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.